PUT - SPRINTER OPEN END - BRISTOL-MYERS SQUIBB | Delayed Deutsche Boerse AG 11:24:14 10/06/2024 pm IST | ||
| 3.3 EUR | -2.65% |
|
| 3 months | +50.00% | ||
| 6 months | +32.42% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 10/24/10 | 3.3 | -2.65% |
| 07/24/07 | 3.39 | +0.59% |
| 06/24/06 | 3.37 | 0.00% |
| 05/24/05 | 3.37 | +2.12% |
| 04/24/04 | 3.3 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 10, 2024 at 11:24 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VU0QS8 |
| ISIN | DE000VU0QS82 |
| Date issued | 12/12/2022 |
| Strike | 77.81 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.07 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.48 € |
|---|---|
| Lowest since issue | 0.065 € |
| Spread | 0.01 € |
| Spread % | 0.30% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.48
USD
Average target price
53.19
USD
Spread / Average Target
+28.24%
- Stock Market
- Certificates
- Certificat
